Bank of New York Mellon Corp Acquires 25,163 Shares of Vaxcyte, Inc. $PCVX

Bank of New York Mellon Corp lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 474,526 shares of the company’s stock after acquiring an additional 25,163 shares during the quarter. Bank of New York Mellon Corp’s holdings in Vaxcyte were worth $27,575,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the period. Allworth Financial LP boosted its stake in Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after acquiring an additional 731 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $86.00.

Vaxcyte Stock Up 1.5%

Shares of NASDAQ PCVX opened at $55.50 on Tuesday. The company has a market cap of $8.01 billion, a P/E ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The business has a 50-day simple moving average of $52.71 and a two-hundred day simple moving average of $54.71.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the company posted ($1.04) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 22,461 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares in the company, valued at approximately $24,921,907.50. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the sale, the chief operating officer owned 158,494 shares in the company, valued at $7,848,622.88. This trade represents a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 75,448 shares of company stock valued at $4,091,197. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.